H.C. Wainwright rates Telix stock Buy as Telix agrees to buy ITM for USD 1.65 billion

Telix Pharmaceuticals (ISIN AU000000TLX2) had a Lang & Schwarz prior close of EUR 9.43 dated October 2, 2026, while H.C. Wainwright's Buy rating and USD 20.00 target were reported on October 1, 2026 by MarketBeat. The company had agreed on September 21, 2026 to acquire ITM for USD 1.65 billion, making the transaction the main strategic issue around Telix stock.

ITM adds scale to radiopharma

According to Telix Pharmaceuticals on September 21, 2026, the upfront consideration comprises USD 1.65 billion on a cash-free and debt-free basis. The sellers are expected to receive USD 1.25 billion in Telix shares, while Telix would assume USD 302 million of net debt.

The transaction also includes up to USD 700 million in contingent consideration tied to regulatory approvals and commercial sales milestones for ITM-11. Telix shareholders are expected to own 76.30 percent of the combined company after completion, compared with 23.70 percent for ITM shareholders.

Revenue growth supports the deal

Telix entered the transaction with fresh operating momentum. Quartr reported that H1 2026 revenue rose 22.00 percent year over year to USD 477.30 million, while net profit reached USD 38.30 million. The comparison matters because the deal is being presented alongside an already scaled commercial business rather than as a standalone pipeline bet.

The same H1 2026 summary said Telix's 2026 guidance was trending toward the upper end of its range. The company also expects the combined organization to generate more than USD 1.30 billion of pro forma 2026 revenue and income, although that figure remains a management estimate tied to completion and integration assumptions.

Analyst target stays above the reference

MarketBeat said H.C. Wainwright reissued its Buy rating and USD 20.00 target, while Wedbush retained an Outperform rating with a USD 22.00 target on September 23, 2026. The analyst targets refer to the US-listed instrument in USD and are therefore separate from the EUR reference value used for German investors.

Telix's primary commercial focus is radiopharmaceuticals for cancer imaging and targeted treatment. The ITM agreement expands that model into isotope production and adds a late-stage therapeutic pipeline, but shareholder approval, regulatory clearances and closing conditions remain material execution points.

Prior close sets the euro reference

Telix's prior close at Lang & Schwarz was EUR 9.43 on October 2, 2026. The quote timestamp was October 4, 2026 at 7:04 p.m. CEST, so the data does not provide a valid October 5 intraday price or daily percentage change.

More news and analyses on Telix Pharmaceuticals stock